No abstract

We studied antibody spectrum in antisera to IgG-like recombinant N-domain of pregnancyspecific glycoprotein-1 (rPSG-N) from E. coli cells. In three experimental series, the fraction of IgG antibodies from anti-rPSG-N sera was immobilized on 3 immunoadsorbents: by polymerization with glutaraldehyde, on glutaraldehyde activated biogel P-300, and on commercial CNBr-activated 4B sepharose. Retroplacental serum was incubated with immobilized antibodies to rPSG1-N, protein was eluted and tested in the precipitation test in standard test systems with PSG1, IgG, and human serum albumin. Three proteins were eluted from all 3 immunoadsorbents: PSG1, IgG, and human serum albumin, which demonstrated the spectrum of antibodies to 3 proteins present also in natural serum PSG1 complex. The proportions of PSG1 and IgG obtained in these experiments were similar to those in natural serum PSG1 complex, while the level of human serum albumin was significantly higher in natural PSG1 complex. Thus, we failed to obtain PSG1 monoprotein free from IgG and human serum albumin. Antigenic mosaicism of the polypeptide chain of IgG-like rPSG1-N relative to the antigenic polyvalence of the complex of three proteins present in bioactive preparation of natural serum PSG1 was discussed.

A set of embryonic proteins -potential markers for ovarian tumors is presented. More than ten new embryonic proteins have been tested, but no one strictly specific protein marker for diagnosis of ovarian tumors has been revealed. SOVA-1 is the most perspective marker for today. The special attention is given to peculiarities of evolution and mechanisms of early distribution of the tumor process. The role of pregnancy and "pregnancy specific glycoprotein"-PSG as a way of the ovary tumor disease prevention is discussed. An attempt to realize sources and logic of the disease is undertaken in the present work. Keywords

Background. This article highlights the main approaches to the treatment of patients with endocrine orbitopathy (EO) and current opportunities for planning and conducting personalized orbital decompression, including the use of Computer-Aided Design (CAD) / Computer-Aided Manufacturing (CAM) technologies. Optimization of treatment of this pathology which can lead to changes in appearance, inability to perform usual work, social isolation, and in the most difficult cases to vision loss is a topical issue of ophthalmology and maxillofacial surgery. The aim. To analyze current information on basic approaches to the treatment of patients with endocrine orbitopathy and the possibility of using computer technologies for planning and performing personalized orbital decompression. Results. The use of corticosteroids, radiation therapy, surgical treatment are the key methods used to manage patients with EO. The use of CAD/CAM technologies allows to plan surgery according to the morphological features of the orbit of each patient. This can potentially affect the outcome of decompression and reduction of exophthalmos, as well as intraoperative complications. When using standard approaches, the results of decompression may vary significantly due to the differences in morphological parameters of the orbits. This dictates the need for a personalized approach to the management of patients with EO. Due to the significant variability of morphological parameters of the orbits in the case of standard approaches, the results in different patients can differ significantly, which dictates the need for a personalized approach to the management of patients with EA. Conclusions. EUGOGO 2016 recommends a multidisciplinary step-by-step approach to the management of patients with EO, depending on its activity and severity and the impact on the patient’s quality of life. A personalized approach using computer simulations and the development of surgical navigation templates for surgical decompression of the orbit will ensure optimal functional and aesthetic treatment results. Keywords: endocrine orbitopathy, treatment, orbital decompression, ComputerAided Design (CAD) / Computer-Aided Manufacturing (CAM) technologies, personalized approach.